<DOC>
	<DOC>NCT00624065</DOC>
	<brief_summary>Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (&lt;140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitrated over a 6 week period until target blood pressure (&lt;140/90mmHg) is met. The primary objective of the study is to compare the proportion of subjects who achieve target blood pressure after 6 weeks of treatment.</brief_summary>
	<brief_title>Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Male or female age 1880 years; stage 1 or 2 hypertension currently receiving 0 or 1 antihypertensive medication; mean sitting systolic blood pressure &gt;/=140mmHg to &lt;/=170mmHg, or mean sitting diastolic blood pressure &gt;/=90 to &lt;/=105mmHg. Subjects taking one hypertensive medication had their medication withdrawn and entered a washout phase prior to randomization. Subject taking two or more antihypertensive medications, known contraindication to angiotensinconverting enzyme (ACE) inhibitors or alpha or betablocker therapy, subject has Type 1 or Type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>target blood pressure</keyword>
	<keyword>hypertension</keyword>
	<keyword>COREG CR</keyword>
	<keyword>carvedilol CR</keyword>
	<keyword>Stage 1 or 2 essential hypertension</keyword>
	<keyword>lisinopril</keyword>
</DOC>